Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update
-
Published:2021-12
Issue:
Volume:
Page:
-
ISSN:0960-9776
-
Container-title:The Breast
-
language:en
-
Short-container-title:The Breast
Author:
Brown Lauren C.,
Loi ShereneORCID
Subject
General Medicine,Surgery
Reference35 articles.
1. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial;Schmid;Lancet Oncol,2020
2. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial;Cortes;Lancet,2020
3. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer;Schmid;N Engl J Med,2018
4. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study;Loibl;Ann Oncol,2019
5. Pembrolizumab for early triple-negative breast cancer;Schmid;N Engl J Med,2020
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献